This study revealed the antiobesity effects of this compound through the activation of the TGR5 and FXR signaling pathways and its capacity to mitigate obesity and lipid metabolism issues by enhancing intestinal barrier dysfunction and reducing intestinal inflammation. This evidence concerns the gene GPBAR1 and obesity due to melanocortin 4 receptor deficiency.